GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Net Cash per Share

Endologix (Endologix) Net Cash per Share : $-11.71 (As of Jun. 2020)


View and export this data going back to 1996. Start your Free Trial

What is Endologix Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Endologix's Net Cash per Share for the quarter that ended in Jun. 2020 was $-11.71.

The historical rank and industry rank for Endologix's Net Cash per Share or its related term are showing as below:

ELGXQ's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.19
* Ranked among companies with meaningful Price-to-Net-Cash only.

Endologix Net Cash per Share Historical Data

The historical data trend for Endologix's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Net Cash per Share Chart

Endologix Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.41 -24.14 -27.74 -22.22 -11.15

Endologix Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.60 -11.25 -11.15 -10.80 -11.71

Competitive Comparison of Endologix's Net Cash per Share

For the Medical Instruments & Supplies subindustry, Endologix's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endologix's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Endologix's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Endologix's Price-to-Net-Cash falls into.



Endologix Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Endologix's Net Cash per Share for the fiscal year that ended in Dec. 2019 is calculated as

Net Cash per Share (A: Dec. 2019 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(41.56-243.308-0)/18.0985
=-11.15

Endologix's Net Cash per Share for the quarter that ended in Jun. 2020 is calculated as

Net Cash per Share (Q: Jun. 2020 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(18.496-242.998-0)/19.1738
=-11.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endologix  (OTCPK:ELGXQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Endologix Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Endologix's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Endologix (Endologix) Business Description

Traded in Other Exchanges
N/A
Address
2 Musick, Irvine, CA, USA, 92618
Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.
Executives
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko director, officer: CEO and Director C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Matthew Thompson officer: Chief Medical Officer 2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady officer: Controller and Corp Secretary 2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto officer: Interim CFO 2 MUSICK IRVINE CA 92618
Jeff Fecho officer: Chief Quality Officer ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob officer: Chief Financial Officer 2 MUSICK IRVINE CA 92618
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John Zehren officer: Chief Commercial Officer 2 MUSICK IRVINE CA 92618
Jeremy B. Hayden officer: General Counsel 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F director 2 MUSICK IRVINE CA 92618